| Market Capitalization (Millions $) |
2,115 |
| Shares
Outstanding (Millions) |
136 |
| Employees |
275 |
| Revenues (TTM) (Millions $) |
331 |
| Net Income (TTM) (Millions $) |
-43 |
| Cash Flow (TTM) (Millions $) |
41 |
| Capital Exp. (TTM) (Millions $) |
10 |
Business Description
Dynavax Technologies Corp is a clinical-stage biopharmaceutical company that develops and commercializes novel vaccines and therapeutics to prevent infectious diseases, cancer, and chronic inflammatory diseases. The company is headquartered in Emeryville, California, and was founded in 199
Dynavax's proprietary technology platforms include the Toll-like Receptor (TLR) and the C-Class CpG deoxyribonucleic acid (CpG DNA) technologies. These platforms stimulate the innate immune system and enhance the body's immune response to various pathogens and tumor antigens.
The company's lead product candidate is HEPLISAV-B, which is an adult hepatitis B vaccine designed to provide faster and more effective protection against hepatitis B compared to traditional vaccines. HEPLISAV-B was approved by the US Food and Drug Administration (FDA) in November 201
Dynavax is also developing SD-101, an investigational TLR9 agonist in phase 3 clinical trials for the treatment of advanced melanoma in combination with Keytruda. The company is also developing DV281, an investigational TLR7/8 agonist in phase 1 clinical trials for the treatment of non-small cell lung cancer.
In addition, Dynavax has partnerships and collaborations with several leading pharmaceutical companies and organizations, including AstraZeneca, GlaxoSmithKline, and the Bill & Melinda Gates Foundation.
Dynavax has a strong financial position, with a market capitalization of approximately $5 billion as of September 202 The company's total revenue for the second quarter of 2021 was $28.1 million, compared to $0 million for the same period in 2020. The company's net loss for the second quarter of 2021 was $68.7 million, compared to $31 million for the same period in 2020.
Overall, Dynavax Technologies Corp is a leading biopharmaceutical company with a promising pipeline of innovative vaccines and therapeutics for the prevention and treatment of infectious and chronic diseases. The company's unique technology platforms and strategic partnerships position it well for continued success in the biopharmaceutical industry.
Company Address: 2100 Powell Street Emeryville 94608 CA
Company Phone Number: 848-5100 Stock Exchange / Ticker: NASDAQ DVAX
|
0.000%
2.82% 
100 %